Cutaneous T-cell lymphoma refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:21:52 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cutaneous T-cell lymphoma refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of PTX-100 for Patients with Cutaneous T-Cell Lymphoma That Has Returned or Did Not Respond to Previous Treatment https://clinicaltrials.eu/trial/a-study-of-ptx-100-for-patients-with-cutaneous-t-cell-lymphoma-that-has-returned-or-did-not-respond-to-previous-treatment/ Wed, 29 Apr 2026 15:07:59 +0000 https://clinicaltrials.eu/trial/a-study-of-ptx-100-for-patients-with-cutaneous-t-cell-lymphoma-that-has-returned-or-did-not-respond-to-previous-treatment/ This study is looking at Cutaneous T-Cell Lymphoma, which is a type of cancer where certain white blood cells called T-cells become abnormal and affect the skin. The study will test a treatment called PTX-100, which is given through a vein as an infusion. This medication works by targeting specific processes in cancer cells to help stop their growth. The study specifically includes patients who have Mycosis fungoides or Sezary syndrome, which are the most common forms of this disease, as well as some other subtypes of this lymphoma. The treatment will be given on its own, without combining it with other cancer medications.

The purpose of this study is to determine how well PTX-100 works in treating this type of lymphoma in patients whose disease has come back or has not responded to previous treatments. The study will also look at how safe the medication is and how the body processes it. Patients in this study will have already tried at least two other treatments for their disease that either did not work or caused problems they could not tolerate. These previous treatments might have included medications such as interferon, chemotherapy drugs like methotrexate, or other specialized cancer treatments.

During the study, doctors will carefully monitor how the disease responds to PTX-100 by checking skin lesions, measuring abnormal cells in the blood, and looking at any disease that has spread beyond the skin. The study will track various measures including how many patients respond to treatment, how long the response lasts, how long patients live without the disease getting worse, and overall survival. Safety will be monitored throughout by checking for side effects, doing blood tests, measuring vital signs, and performing heart tests called electrocardiograms. Blood samples will also be taken at different times to understand how the body absorbs and processes the medication.

]]> Study of Mogamulizumab and Total Skin Electron Beam Therapy for Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma https://clinicaltrials.eu/trial/study-of-mogamulizumab-and-total-skin-electron-beam-therapy-for-patients-with-stage-ib-iib-cutaneous-t-cell-lymphoma/ Wed, 29 Apr 2026 14:29:49 +0000 https://clinicaltrials.eu/trial/study-of-mogamulizumab-and-total-skin-electron-beam-therapy-for-patients-with-stage-ib-iib-cutaneous-t-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called cutaneous T-cell lymphoma, which affects a kind of white blood cell and primarily involves the skin. The study specifically looks at two subtypes of this cancer: Mycosis Fungoides and Sézary Syndrome. The treatment being tested in this trial is a medication called mogamulizumab, also known by its code names KW-0761 and AMG 761. This medication is being used in combination with a treatment method called Total Skin Electron Beam therapy (TSEB), which involves using a special type of radiation to treat the skin.

The purpose of the study is to evaluate how well this combination treatment works in patients with stage IB to IIB cutaneous T-cell lymphoma. Participants in the study will receive the treatment and be monitored over a period of time to see how their cancer responds. The study will look at various outcomes, including how long patients live without their cancer getting worse, the overall safety of the treatments, and the response rate, which measures how many patients experience a reduction in their cancer.

Throughout the study, researchers will also assess other factors such as the overall survival of patients, the time it takes for the cancer to progress, and the duration of any positive response to the treatment. Additionally, the study will explore the impact of the treatment on patients’ quality of life. The trial is designed to gather important information that could help improve treatment options for people with this type of cancer in the future.

]]> Study of Linperlisib for Patients with Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma https://clinicaltrials.eu/trial/study-of-linperlisib-for-patients-with-relapsed-or-refractory-peripheral-t-nk-cell-or-cutaneous-t-cell-lymphoma/ Wed, 29 Apr 2026 14:25:04 +0000 https://clinicaltrials.eu/trial/study-of-linperlisib-for-patients-with-relapsed-or-refractory-peripheral-t-nk-cell-or-cutaneous-t-cell-lymphoma/ This clinical trial is focused on studying the effectiveness and safety of a medication called Linperlisib (also known by its code name YY-20394) in treating certain types of lymphoma. Lymphoma is a type of cancer that affects the lymphatic system, which is part of the body’s immune system. The specific types of lymphoma being studied in this trial are Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma. These are conditions where the cancerous cells are either in the lymph nodes or the skin. The trial is designed for patients whose lymphoma has returned after treatment or has not responded to previous treatments.

The purpose of this study is to evaluate how well Linperlisib works in treating these lymphomas. Participants in the study will take Linperlisib in the form of a tablet. The study will monitor the participants over a period of time to see how their lymphoma responds to the treatment. This includes checking if the cancer shrinks or disappears and observing any side effects that may occur. The study will also look at how long the response lasts and how the treatment affects the participants’ overall health and survival.

Participants will be closely monitored by a team of healthcare professionals throughout the study. This includes regular check-ups and tests to assess the progress of the treatment. The study aims to provide valuable information on the potential benefits and risks of using Linperlisib for treating these specific types of lymphoma. The results of this study could help improve treatment options for patients with these challenging conditions in the future.

]]>